Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

630 questions · 634 findings · 285 reviews

No studies found 316 · 49.8%GRADE not reported 40 · 6.3%Very low 95 · 15%Low 111 · 17.5%Moderate 60 · 9.5%High 12 · 1.9%

Intervention not reported

Quality of life · Patients with chronic non‐specific neck pain

The review found no eligible studies for this question.

1 finding from 1 review

Intervention not reported

Quality of life · Patients with subacute/chronic neck pain with or without radicular symptoms and cervicogenic headache

The review found no eligible studies for this question.

1 finding from 1 review

Amifostine vs no treatment/placebo

Quality of life (Patient Benefit Questionnaire, 10-point scale) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region

It is very uncertain whether amifostine changes quality of life (Patient Benefit Questionnaire, 10-point scale) compared with no treatment/placebo (very low certainty).

1 finding from 1 review

Selenium vs no intervention

Quality of life and other oral related symptoms (loss of taste, dysphagia) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
1 finding from 1 review

Any antifungal intervention for the treatment of oral candidiasis vs Placebo, no treatment, or another active antifungal intervention

Patient quality of life · Patients with cancer receiving chemotherapy and/or radiotherapy with overt oral candidiasis

The review found no eligible studies for this question.

1 finding from 1 review

Antifungal drugs absorbed from GI tract (fluconazole, ketoconazole, itraconazole) vs placebo or no treatment

Patient quality of life · Patients with cancer receiving chemotherapy and/or radiotherapy

The review found no eligible studies for this question.

1 finding from 1 review

ALK inhibitor vs any cytotoxic chemotherapy

Health‐related quality of life: time to deterioration in composite endpoint (cough, dyspnoea, and chest pain) · advanced anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer

ALK inhibitor leads to lower health‐related quality of life: time to deterioration in composite… compared with any cytotoxic chemotherapy (high certainty).

1 finding from 1 review

Intervention not reported

Quality of life (QoL) We reported this outcome narratively in this review. Here, long‐term results (i.e., at the end of treatment) are presented. In the comparison PAZ versus SUN, QoL was measured using FACIT‐F (score range 0‐52; higher scores rep... · people with a confirmed diagnosis of advanced renal cell carcinoma (combined risk groups) without previous systemic anticancer therapy

The review found no eligible studies for this question.

1 finding from 1 review